WINNIPEG, MANITOBA -- (MARKET WIRE) -- February 21, 2007 -- Miraculins Inc. (TSX VENTURE: MOM), a biotechnology company dedicated to the discovery and validation of cancer biomarkers for use in developing diagnostic tools and therapeutic products is pleased to announce the completion of patient enrollment in its PCSC04 study.
